Allergan and Jan Marini to settle patent infringement suit

The dismissal is based on Jan Marini acknowledging the validity of Allergan’s relevant patents covering the use of certain drug substances, such as prostaglandin analogs, to promote eyelash enhancement and also agreeing to cease its distribution of eyelash products containing these ingredients in the US and other countries worldwide where Allergan owns related patents.

Douglas Ingram, chief administrative officer of Allergan, said: “We are pleased that Jan Marini has acknowledged that Allergan’s US and foreign eyelash growth patents are valid and enforceable and has agreed to cease further distribution of its eyelash growth products.”